{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:40:32Z","timestamp":1792597232942,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011710","name":"Shaanxi Province Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009581","name":"Shaanxi Province Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ijantimicag.2024.107331","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T17:30:55Z","timestamp":1725730255000},"page":"107331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of vonoprazan and high-dose amoxicillin dual therapy in eradicating Helicobacter pylori: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"64","author":[{"given":"Ju","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Mei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Jun","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Meng","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Quan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ijantimicag.2024.107331_bib0001","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","article-title":"Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107331_bib0002","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","article-title":"Helicobacter pylori infection","volume":"9","author":"Malfertheiner","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ijantimicag.2024.107331_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"issue":"24","key":"10.1016\/j.ijantimicag.2024.107331_bib0004","first-page":"2899","article-title":"2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment","volume":"135","author":"Zhou","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"10.1016\/j.ijantimicag.2024.107331_bib0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MCG.0000000000001719","article-title":"Helicobacter pylori World Gastroenterology Organization Global Guideline","volume":"57","author":"Katelaris","year":"2023","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.ijantimicag.2024.107331_bib0006","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40265-023-01991-5","article-title":"Vonoprazan: a review in Helicobacter pylori infection","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.ijantimicag.2024.107331_bib0007","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/jgh.15917","article-title":"Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"37","author":"Ouyang","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107331_bib0008","doi-asserted-by":"crossref","first-page":"e13039","DOI":"10.1111\/hel.13039","article-title":"Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: a systematic review and meta-analysis","volume":"29","author":"Du","year":"2024","journal-title":"Helicobacter"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107331_bib0009","doi-asserted-by":"crossref","first-page":"e13054","DOI":"10.1111\/hel.13054","article-title":"Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis","volume":"29","author":"Ju","year":"2024","journal-title":"Helicobacter"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107331_bib0010","doi-asserted-by":"crossref","first-page":"e13040","DOI":"10.1111\/hel.13040","article-title":"Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"29","author":"Zhou","year":"2024","journal-title":"Helicobacter"},{"issue":"4","key":"10.1016\/j.ijantimicag.2024.107331_bib0011","doi-asserted-by":"crossref","first-page":"e12970","DOI":"10.1111\/hel.12970","article-title":"Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: a multicenter randomized controlled trial in China","volume":"28","author":"Hu","year":"2023","journal-title":"Helicobacter"},{"issue":"7","key":"10.1016\/j.ijantimicag.2024.107331_bib0012","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1007\/s10238-023-01074-5","article-title":"Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study","volume":"23","author":"Peng","year":"2023","journal-title":"Clin Exp Med"},{"issue":"4","key":"10.1016\/j.ijantimicag.2024.107331_bib0013","doi-asserted-by":"crossref","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","article-title":"Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy","volume":"118","author":"Qian","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2024.107331_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231190976","article-title":"Efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori first-line treatment: a single-center, randomized, controlled trial","volume":"16","author":"Wang","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"issue":"41","key":"10.1016\/j.ijantimicag.2024.107331_bib0015","doi-asserted-by":"crossref","first-page":"e35610","DOI":"10.1097\/MD.0000000000035610","article-title":"A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori","volume":"102","author":"Yang","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107331_bib0016","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12876-024-03225-8","article-title":"Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"10.1016\/j.ijantimicag.2024.107331_bib0017","doi-asserted-by":"crossref","first-page":"e37476","DOI":"10.1097\/MD.0000000000037476","article-title":"Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: a propensity score matching analysis","volume":"103","author":"Liu","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.ijantimicag.2024.107331_bib0018","first-page":"655","article-title":"Ten-day vonoprazan-amoxicillin dual therapy vs standard 14-day bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: a multicenter randomized clinical trial","volume":"119","author":"Yan","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.ijantimicag.2024.107331_bib0019","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00535-023-02042-2","article-title":"Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study","volume":"58","author":"Han","year":"2023","journal-title":"J Gastroenterol"},{"issue":"5","key":"10.1016\/j.ijantimicag.2024.107331_bib0020","doi-asserted-by":"crossref","first-page":"e13003","DOI":"10.1111\/hel.13003","article-title":"Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: a propensity score matching analysis","volume":"28","author":"Su","year":"2023","journal-title":"Helicobacter"},{"issue":"3","key":"10.1016\/j.ijantimicag.2024.107331_bib0021","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/cpdd.1357","article-title":"Clinical study on the eradication of Helicobacter pylori by vonoprazan combined with amoxicillin for 10-day dual therapy","volume":"13","author":"Yan","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"10.1016\/j.ijantimicag.2024.107331_bib0022","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1016\/j.ijantimicag.2024.107331_bib0023","doi-asserted-by":"crossref","first-page":"987","DOI":"10.21037\/atm-22-4133","article-title":"The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study","volume":"10","author":"Lin","year":"2022","journal-title":"Ann Transl Med"},{"issue":"3","key":"10.1016\/j.ijantimicag.2024.107331_bib0024","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.gtc.2010.08.007","article-title":"Pharmacologic aspects of eradication therapy for Helicobacter pylori infection","volume":"39","author":"Furuta","year":"2010","journal-title":"Gastroenterol Clin North Am"},{"issue":"7","key":"10.1016\/j.ijantimicag.2024.107331_bib0025","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/pathogens11070786","article-title":"Primary antibiotic resistance of Helicobacter pylori in different regions of China: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2022","journal-title":"Pathogens"},{"issue":"8","key":"10.1016\/j.ijantimicag.2024.107331_bib0026","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.14309\/ajg.0000000000001828","article-title":"Helicobacter pylori antibiotic resistance in the United States between 2011 and 2021: a systematic review and meta-analysis","volume":"117","author":"Ho","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.ijantimicag.2024.107331_bib0027","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/00498254.2016.1203505","article-title":"In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker","volume":"47","author":"Yamasaki","year":"2017","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.ijantimicag.2024.107331_bib0028","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000529622","article-title":"Efficacy and safety of vonoprazan and amoxicillin dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"104","author":"Zhang","year":"2023","journal-title":"Digestion"},{"issue":"6","key":"10.1016\/j.ijantimicag.2024.107331_bib0029","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/sjg.sjg_153_23","article-title":"Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Zhou","year":"2023","journal-title":"Saudi J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107331_bib0030","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s40001-023-01249-6","article-title":"The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis","volume":"28","author":"Feng","year":"2023","journal-title":"Eur J Med Res"},{"issue":"6","key":"10.1016\/j.ijantimicag.2024.107331_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107159","article-title":"Helicobacter pylori eradication with high-dose proton pump inhibitor-amoxicillin dual therapy: a systematic review and meta-analysis","volume":"63","author":"Yeh","year":"2024","journal-title":"Int J Antimicrob Agents"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T10:54:49Z","timestamp":1730717689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924002474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0924857924002474"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107331","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of vonoprazan and high-dose amoxicillin dual therapy in eradicating Helicobacter pylori: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107331"}}